Pharmacyclics Inc. (PCYC) announced that it has priced an underwritten registered public offering of 2.20 million shares of its common stock at a public offering price of $94.20 per share. The public offering represents about 3.1% of the shares of common stock currently outstanding. The offering is expected to close on March 13, 2013, subject to customary closing conditions.
J.P. Morgan Securities LLC is acting as sole manager for the offering. The company said it has granted the underwriter a 30-day option to purchase up to an additional 330,000 shares of common stock to cover over-allotments, if any.
The company noted that it intends to use the net proceeds from this offering to accelerate commercial readiness for Ibrutinib post Breakthrough Therapy Designation, to advance its clinical pipeline, including expanding clinical development of Ibrutinib in additional indications, to evaluate strategic opportunities to potentially add synergistic assets, and for general corporate purposes.
For comments and feedback: editorial@rttnews.com